Photodynamic Therapy and Imaging Based On Tumor-Targeted Nanoprobe, Polymer-Conjugated Zinc Protoporphyrin

References

• McBride G . Studies expand potential uses of photodynamic therapy. J. Natl Cancer Inst.94(23), 1740–1742 (2002).
   PubMedGoogle Scholar
• Wilson BC . Photodynamic therapy for cancer: principles. Can. J. Gastroenterol.16(6), 393–396 (2002).
   PubMedGoogle Scholar
• Dolmans DE , FukumuraD, JainRK. Photodynamic therapy for cancer. Nat. Rev. Cancer3(5), 380–387 (2003).
   PubMed Web of Science ®Google Scholar
• Nowis D , LegatM, GrzelaTet al. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene25(24), 3365–3374 (2006).
   PubMed Web of Science ®Google Scholar
• Fang J , SekiT, MaedaH. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev.61(4), 290–302 (2009).
   PubMed Web of Science ®Google Scholar
• Fang J , NakamuraH, MaedaH. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev.63(3), 136–151 (2011).
   PubMed Web of Science ®Google Scholar
• Matsumura Y , MaedaH. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res.46(12 Pt 1), 6387–6392 (1986).
   PubMed Web of Science ®Google Scholar
• Duncan R , VicentMJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv. Drug Deliv. Rev.65(1), 60–70 (2013).
   PubMed Web of Science ®Google Scholar
• Torchilin V . Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev.63(3), 131–135 (2011).
   PubMed Web of Science ®Google Scholar
• Liu J , OhtaS, SonodaAet al. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy. J. Control. Release117(1), 104–110 (2007).
   PubMed Web of Science ®Google Scholar
• Sibani SA , McCarronPA, WoolfsonAD, DonnellyRF. Photosensitiser delivery for photodynamic therapy. Part 2: systemic carrier platforms. Expert Opin. Drug Deliv.5(11), 1241–1254 (2008).
   PubMed Web of Science ®Google Scholar
• Oh IH , MinHS, LiLet al. Cancer cell-specific photoactivity of pheophorbide a-glycol chitosan nanoparticles for photodynamic therapy in tumor-bearing mice. Biomaterials34(27), 6454–6463 (2013).
   PubMed Web of Science ®Google Scholar
• Shiah JG , SunY, PetersonCM, StraightRC, KopecekJ. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments. Clin. Cancer Res.6(3), 1008–1015 (2000).
   PubMed Web of Science ®Google Scholar
• Regehly M , GreishK, RancanF, MaedaH, BöhmF, RöderB. Water-soluble polymer conjugates of ZnPP for photodynamic tumor therapy. Bioconjug. Chem.18(2), 494–499 (2007).
   PubMed Web of Science ®Google Scholar
• Iyer AK , GreishK, SekiTet al. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J. Drug Target.15(7–8), 496–506 (2007).
   PubMed Web of Science ®Google Scholar
• Nakamura H , LiaoL, HitakaYet al. Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo. J. Control. Release165(3), 191–198 (2013).
   PubMed Web of Science ®Google Scholar
• Jin CS , CuiL, WangF, ChenJ, ZhengG. Targeting-triggered porphysome nanostructure disruption for activatable photodynamic therapy. Adv. Healthc. Mater.3(8), 1240–1249 (2014).
   PubMed Web of Science ®Google Scholar
• Gabriel D , ZuluagaMF, LangeN. On the cutting edge: protease-sensitive prodrugs for the delivery of photoactive compounds. Photochem. Photobiol. Sci.10(5), 689–703 (2011).
   PubMed Web of Science ®Google Scholar
• Fang J , AkaikeT, MaedaH. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis9(1), 27–35 (2004).
   PubMed Web of Science ®Google Scholar
• Sahoo SK , SawaT, FangJet al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug. Chem.13(5), 1031–1038 (2002).
   PubMed Web of Science ®Google Scholar
• Fang J , SawaT, AkaikeTet al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res.63(13), 3567–3574 (2003).
   PubMed Web of Science ®Google Scholar
• Iyer AK , GreishK, FangJ, MurakamiR, MaedaH. High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor. Biomaterials28(10), 1871–1881 (2007).
   PubMed Web of Science ®Google Scholar
• Fang J , GreishK, QinHet al. HSP32 (HO-1) inhibitor, copoly(styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: in vitro and in vivo anticancer effect. Eur. J. Pharm. Biopharm.81(3), 540–547 (2012).
   PubMed Web of Science ®Google Scholar
• Editorial . Welcome clinical leadership at NICE. Lancet372(9639), 601 (2008).
   PubMed Web of Science ®Google Scholar
• Tol J , KoopmanM, CatsAet al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med.360(6), 563–572 (2009).
   PubMed Web of Science ®Google Scholar
• Fojo T , GradyC. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst.101(15), 1044–1048 (2009).
   PubMedGoogle Scholar
• Taieb J , TaberneroJ, MiniEet al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol.15(8), 862–873 (2014).
   PubMed Web of Science ®Google Scholar
• Wood LD , ParsonsDW, JonesSet al. The genomic landscapes of human breast and colorectal cancers. Science318(5853), 1108–1113 (2007).
   PubMed Web of Science ®Google Scholar
• Sjöblom T , JonesS, WoodLDet al. The consensus coding sequences of human breast and colorectal cancers. Science314(5797), 268–274 (2006).
   PubMed Web of Science ®Google Scholar
• Vicent MJ , RingsdorfH, DuncanR. Polymer therapeutics: clinical applications and challenges for development. Adv. Drug Deliv. Rev.61(13), 1117–1120 (2009).
   PubMed Web of Science ®Google Scholar
• Duncan R . The dawning era of polymer therapeutics. Nat. Rev. Drug Discov.2(5), 347–360 (2003).
   PubMed Web of Science ®Google Scholar
• Matsumura Y , KataokaK. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci.100(4), 572–579 (2009).
   PubMed Web of Science ®Google Scholar
• Dougherty TJ , GomerCJ, HendersonBWet al. Photodynamic therapy. J. Natl Cancer Inst.90(12), 889–905 (1998).
   PubMed Web of Science ®Google Scholar
• Moan J , IaniV, MaLW. Choice of the proper wavelength for photochemotherapy. In: Photochemotherapy Photodynamic Therapy and Other Modalities. EhrenbergB, JoriG, MoanJ ( Eds). Proc SPIE, Bellingham, Washington, DC, USA, 2625, 544–549 (1996).
   Google Scholar
• Rigual NR , ShafirsteinGet al. Adjuvant intraoperative photodynamic therapy in head and neck cancer. JAMA Otolaryngol. Head Neck Surg.139(7), 706–711 (2013).
   PubMed Web of Science ®Google Scholar
• Yano T , MutoM, MinashiKet al. Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. Int. J. Cancer131(5), 1228–1234 (2012).
   PubMed Web of Science ®Google Scholar
• Kobayashi W , LiuQ, NakagawaHet al. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse. Oral Oncol.42(1), 46–50 (2006).
   PubMed Web of Science ®Google Scholar
• Pech O , NagyCD, GossnerL, MayA, EllC. Photodynamic therapy of human Barrett's cancer using 5-aminolaevulinic acid-induced protoporphyrin IX: an in-vivo dosimetry study in athymic nude mice. Eur. J. Gastroenterol. Hepatol.14(6), 657–662 (2002).
   PubMed Web of Science ®Google Scholar
• Seshadri M , BellnierDA, VaughanLAet al. Light delivery over extended time periods enhances the effectiveness of photodynamic therapy. Clin. Cancer Res.14(9), 2796–2805 (2008).
   PubMed Web of Science ®Google Scholar
• Henderson BW , BuschTM, VaughanLAet al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res.60(3), 525–529 (2000).
   PubMed Web of Science ®Google Scholar
• Busch TM , WileytoEP, EmanueleMJet al. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. Cancer Res.62(24), 7273–7279 (2002).
   PubMed Web of Science ®Google Scholar
• Sitnik TM , HamptonJA, HendersonBW. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br. J. Cancer77(9), 1386–1394 (1998).
   PubMed Web of Science ®Google Scholar
• Duncan R , Sat-KlopschYN, BurgerAM, BibbyMC, FiebigHH, SausvilleEA. Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother. Pharmacol.72(2), 417–427 (2013).
   PubMed Web of Science ®Google Scholar
• Tsukigawa K , NakamuraH, FangJet al. Effect of different chemical bonds in pegylation of zinc protoporphyrin that affects drug release, intracellular uptake, and therapeutic effect in the tumor. Eur J Pharm Biopharm.89, 259–270 (2015).
   PubMed Web of Science ®Google Scholar
• Nakamura H , EtrychT, ChytilPet al. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J. Control. Release174, 81–87 (2014).
   PubMed Web of Science ®Google Scholar
• Malugin A , KopeckováP, KopecekJ. Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J. Control. Release124(1–2), 6–10 (2007).
   PubMed Web of Science ®Google Scholar